Pancreatic Cancer Research

ResearcherFukushima Medical UniversityActive in the last 2 years

Shigeru Marubashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5263-3286; OpenAlex author ID A5001408222, A5044057885. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
111
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 3 papers · 2014: 2 papers · 2015: 6 papers · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 26

  1. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. γ1-adaptin expression is associated with cancer progression and poor prognosis in pancreatic ductal adenocarcinoma: Cellular and histopathological analyses Co-author DOI 10.21203/rs.3.rs-9301878/v1↗
  4. Evaluating preoperative gemcitabine-based chemoradiation for resectable and borderline resectable pancreatic cancer: a phase 1 study. Last author DOI 10.5387/fms.25-00013↗
  5. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  6. A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fin… Co-author DOI 10.5946/ce.2022.019↗
  7. [A Case of Pancreatic Cancer That Developed Peritoneal Recurrence after Radical Surgery following Neoadjuvant Chemoradiation Therapy(NACRT)with Pathological Co… Last author PMID 38247070↗
  8. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.9626↗
  9. [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases]. Last author PMID 31164525↗
  10. Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23377↗
  11. c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. Co-author DOI 10.3892/ol.2018.8793↗
  12. A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. Co-author DOI 10.3892/ijo.2015.3258↗
  13. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Co-author DOI 10.3892/ol.2015.4057↗
  14. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on opera… Co-author DOI 10.1016/j.surg.2014.09.022↗
  15. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Co-author DOI 10.1093/jjco/hyu224↗
  16. Susceptibility of pancreatic cancer stem cells to reprogramming. Co-author DOI 10.1111/cas.12734↗
  17. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Co-author DOI 10.3892/mco.2015.490↗
  18. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Co-author DOI 10.3892/ol.2015.3667↗
  19. [Three Resected Cases of Metachronous Pancreatic Cancer Successfully Treated with Repeated Pancreatectomy]. Co-author PMID 26805359↗
  20. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1093/jjco/hyu143↗
  21. [A case of initially unresectable pancreatic cancer with arterial invasion successfully resected after chemotherapy]. Co-author PMID 25731236↗
  22. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2013.06.007↗
  23. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0b013e31829b3ce4↗
  24. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.5754/hge12974↗
  25. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Co-author DOI 10.1038/onc.2011.59↗
  26. [A case report of port-site metastasis of pancreatic cancer after laparoscope assistted distal pancreatectomy]. Co-author PMID 22202411↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeyuki Tsukida · 4 shared papers, 2019–2026 · strength 0.85
  2. Teruhide Ishigame · 4 shared papers, 2019–2026 · strength 0.85
  3. Naoya Sato · 4 shared papers, 2019–2026 · strength 0.85
  4. Hidetoshi Eguchi · 15 shared papers, 2011–2026 · strength 0.76
  5. Yuichiro Doki · 14 shared papers, 2011–2018 · strength 0.57
  6. Hiroaki Nagano · 13 shared papers, 2011–2018 · strength 0.53
  7. Shintaro Yagi · 2 shared papers, 2026 · strength 0.39
  8. Etsuro Hatano · 2 shared papers, 2026 · strength 0.39
  9. Naoki Ikenaga · 2 shared papers, 2026 · strength 0.39
  10. Tsutomu Fujii · 2 shared papers, 2026 · strength 0.39
  11. Hirofumi Akita · 5 shared papers, 2011–2026 · strength 0.36
  12. Naoto Gotohda · 2 shared papers, 2025–2026 · strength 0.35
  13. Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.35
  14. Masayuki Ohtsuka · 2 shared papers, 2025–2026 · strength 0.35
  15. Yoshito Tomimaru · 8 shared papers, 2013–2016 · strength 0.33
  16. Hiroyuki Asama · 3 shared papers, 2018–2023 · strength 0.30
  17. Rei Suzuki · 3 shared papers, 2018–2023 · strength 0.30
  18. Mitsuru Sugimoto · 3 shared papers, 2018–2023 · strength 0.30
  19. Tadayuki J. Takagi · 3 shared papers, 2018–2023 · strength 0.30
  20. Hiromasa Ohira · 3 shared papers, 2018–2023 · strength 0.30
  21. Satoshi Waguri · 1 shared paper, 2026 · strength 0.30
  22. Hidenori Takahashi · 4 shared papers, 2011–2026 · strength 0.29
  23. Hideshi Ishii · 5 shared papers, 2015–2018 · strength 0.24
  24. Tadafumi Asaoka · 5 shared papers, 2014–2016 · strength 0.22
  25. Shingo Kagawa · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.